BRPI1006626B8 - uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar - Google Patents

uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar

Info

Publication number
BRPI1006626B8
BRPI1006626B8 BRPI1006626A BRPI1006626A BRPI1006626B8 BR PI1006626 B8 BRPI1006626 B8 BR PI1006626B8 BR PI1006626 A BRPI1006626 A BR PI1006626A BR PI1006626 A BRPI1006626 A BR PI1006626A BR PI1006626 B8 BRPI1006626 B8 BR PI1006626B8
Authority
BR
Brazil
Prior art keywords
lung infection
treat
drug
fluoroquinolone antibiotic
bacterial lung
Prior art date
Application number
BRPI1006626A
Other languages
English (en)
Inventor
Griffit David
Dudley Mike
Rodny Olga
Original Assignee
Mpex Pharmaceuticals Inc
Raptor Pharmaceuticals Inc
Tripex Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43011488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1006626(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mpex Pharmaceuticals Inc, Raptor Pharmaceuticals Inc, Tripex Pharmaceuticals Llc filed Critical Mpex Pharmaceuticals Inc
Publication of BRPI1006626A2 publication Critical patent/BRPI1006626A2/pt
Publication of BRPI1006626B1 publication Critical patent/BRPI1006626B1/pt
Publication of BRPI1006626B8 publication Critical patent/BRPI1006626B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

uso de antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar aqui são revelados métodos para tratar uma infecção bacteriana pulmonar compreendendo bactérias crescendo sob condições anaeróbicas usando um antibiótico fluoroquinolônico. o antibiótico fluoroquinolônico pode, por exemplo, ser levofloxacina ou ofloxacina. também são revelados métodos para inibir bactérias crescendo sob condições anaeróbicas expondo-se as bactérias a uma quantidade de antibiótico fluoroquinolônico eficiente para inibir o crescimento das ditas bactérias.
BRPI1006626A 2009-04-24 2010-04-22 uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar BRPI1006626B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17262509P 2009-04-24 2009-04-24
US61/172,625 2009-04-24
PCT/US2010/032128 WO2010124141A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Publications (3)

Publication Number Publication Date
BRPI1006626A2 BRPI1006626A2 (pt) 2020-07-28
BRPI1006626B1 BRPI1006626B1 (pt) 2021-05-11
BRPI1006626B8 true BRPI1006626B8 (pt) 2021-05-25

Family

ID=43011488

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006626A BRPI1006626B8 (pt) 2009-04-24 2010-04-22 uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar

Country Status (27)

Country Link
US (2) US20120035166A1 (pt)
EP (1) EP2421539B1 (pt)
JP (2) JP6179844B2 (pt)
KR (1) KR20120034626A (pt)
CN (2) CN102427815A (pt)
AU (1) AU2010238765B2 (pt)
BR (1) BRPI1006626B8 (pt)
CA (1) CA2759874C (pt)
CL (1) CL2011002649A1 (pt)
CO (1) CO6450642A2 (pt)
CY (1) CY1122525T1 (pt)
DK (1) DK2421539T3 (pt)
ES (1) ES2755754T3 (pt)
HR (1) HRP20191951T1 (pt)
HU (1) HUE046595T2 (pt)
IL (1) IL215777A (pt)
LT (1) LT2421539T (pt)
MX (1) MX339077B (pt)
MY (1) MY178871A (pt)
NZ (1) NZ596245A (pt)
PL (1) PL2421539T3 (pt)
PT (1) PT2421539T (pt)
RU (1) RU2535056C2 (pt)
SG (3) SG175288A1 (pt)
SI (1) SI2421539T1 (pt)
WO (1) WO2010124141A1 (pt)
ZA (1) ZA201107903B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524734B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
AU2010289326B2 (en) 2009-09-04 2015-09-24 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
CA2905975A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6966835B2 (ja) * 2016-02-05 2021-11-17 ホライズン オーファン リミテッド ライアビリティ カンパニー 嚢胞性線維症のためのフルオロキノロン製剤
CN108849939B (zh) * 2018-07-31 2021-02-19 广东省农业科学院植物保护研究所 盐酸左氧氟沙星在制备用于防治烟草青枯病的农药制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490027A4 (en) * 2002-03-05 2010-11-10 Transave Inc METHODS OF TRAPPING BIOACTIVE AGENT IN A LIPOSOME OR LIPID COMPLEX
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
LT1901749T (lt) * 2005-05-18 2016-10-25 Raptor Pharmaceuticals Inc. Aerozoliniai fluorchinolinai ir jų naudojimas
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2285345A1 (en) 2008-05-15 2011-02-23 Novartis AG Pulmonary delivery of a fluoroquinolone
JP2012505223A (ja) * 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物

Also Published As

Publication number Publication date
NZ596245A (en) 2013-11-29
RU2011145430A (ru) 2013-05-27
CY1122525T1 (el) 2021-01-27
RU2535056C2 (ru) 2014-12-10
JP6179844B2 (ja) 2017-08-16
BRPI1006626A2 (pt) 2020-07-28
CA2759874A1 (en) 2010-10-28
HUE046595T2 (hu) 2020-03-30
PL2421539T3 (pl) 2020-02-28
MX339077B (es) 2016-05-10
HRP20191951T1 (hr) 2021-05-14
SG175288A1 (en) 2011-11-28
CN102427815A (zh) 2012-04-25
AU2010238765B2 (en) 2014-12-18
CN107050032A (zh) 2017-08-18
US20210015811A1 (en) 2021-01-21
EP2421539A4 (en) 2014-01-29
AU2010238765A1 (en) 2011-11-10
PT2421539T (pt) 2019-11-22
JP6228580B2 (ja) 2017-11-08
CL2011002649A1 (es) 2012-06-22
LT2421539T (lt) 2019-12-10
SG10201811494SA (en) 2019-01-30
ES2755754T3 (es) 2020-04-23
MX2011011190A (es) 2012-02-13
BRPI1006626B1 (pt) 2021-05-11
KR20120034626A (ko) 2012-04-12
EP2421539B1 (en) 2019-10-23
IL215777A0 (en) 2012-01-31
WO2010124141A1 (en) 2010-10-28
SI2421539T1 (sl) 2019-12-31
CO6450642A2 (es) 2012-05-31
JP2016053041A (ja) 2016-04-14
SG10201403512TA (en) 2014-08-28
CA2759874C (en) 2016-11-08
EP2421539A1 (en) 2012-02-29
MY178871A (en) 2020-10-21
DK2421539T3 (da) 2019-11-18
US20120035166A1 (en) 2012-02-09
ZA201107903B (en) 2013-01-30
JP2012524811A (ja) 2012-10-18
IL215777A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BRPI1006626B8 (pt) uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar
NZ593111A (en) Antibacterial compounds
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
CR20110195A (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
TN2014000417A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
BR112017027719A8 (pt) Composto, zwitterion, composição farmacêutica, e, uso de um composto
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
MX2012002759A (es) Compuestos quimicos.
BR112014015720A2 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
EA201100447A1 (ru) Органические соединения
NZ616764A (en) Mannose derivatives as antagonists of bacterial adhesion
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
BR112013017974A2 (pt) inibidores de pirimidina girase e topoisomerase iv
MX2021003084A (es) Compuestos antibacterianos.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
MX2013008164A (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
GB201117051D0 (en) Carbonic anhydrase inhibitors
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
BR112014000100A2 (pt) derivados de ácido carboxílico tendo um anel oxazol[5,4-b]piridina
TR201000686A1 (tr) Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: TRIPEX PHARMACEUTICALS, LLC (US)

B25A Requested transfer of rights approved

Owner name: RAPTOR PHARMACEUTICALS INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: HORIZON ORPHAN LLC (US)

B25G Requested change of headquarter approved

Owner name: HORIZON ORPHAN LLC (US)